


Amendments to the Claims

Listing of Claims

1. (Currently Amended) A method for treating acute coronary syndrome or recurrence thereof, in a patient in need thereof, consisting ~~essentially~~ of the following steps performed in any order:

- a) administering a compound of formula I



I


or a pharmaceutically acceptable salt thereof; ~~and~~

- b) performing a percutaneous coronary intervention procedure, and
c) optionally administering aspirin.

2. (Currently Amended) ~~A method for treating according to Claim 1 wherein the compound of formula I is administered in combination with aspirin.~~

A method for treating acute coronary syndrome or recurrence thereof, in a patient in need thereof, consisting of the following steps performed in any order:

- a) administering a compound of formula I




I

or a pharmaceutically acceptable salt thereof; ~~and~~

- b) performing a percutaneous coronary intervention procedure, and
c) administering aspirin.

3. (Currently Amended) A method for treating acute coronary syndrome or recurrence thereof, in a patient in need thereof, consisting ~~essentially~~ of the following steps performed in the order described:

- a) first, administering a compound of formula I



I

or a pharmaceutically acceptable salt thereof, in combination with aspirin;

- b) second, performing a percutaneous coronary intervention procedure;
and
c) third, administering a compound of formula I or a pharmaceutically acceptable salt thereof, in combination with aspirin.

4. (Currently Amended) A method for treating acute coronary syndrome or recurrence thereof, in a patient in need thereof, consisting ~~essentially~~ of in order the steps of:

- a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with aspirin about 2 to 30 days prior to performing the percutaneous coronary intervention procedure,
b) performing a percutaneous coronary intervention procedure, and
c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with aspirin from about 0 to 365 days after performance of the percutaneous coronary intervention procedure.